KRAS and neoplasm: KRAS, in turn, leads to the activation of HIF-1a through the mitogen pathways activated by protein kinase or phosphatidylinositol 3 kinase, leading to cell division, metastatic behavior, drug resistance, and tumor recurrence, associated with poor prognosis [24,25] (Figure 5A).